Developing New Medicines Through Artificial Intelligence
On September 30, 2012, a computer program named “AlexNet” won an international competition and ushered in a new age of artificial intelligence (AI)....
On September 30, 2012, a computer program named “AlexNet” won an international competition and ushered in a new age of artificial intelligence (AI)....
While many biopharmaceutical companies are built to fulfil a need, Resilience was built to serve innovation. Founded during the COVID-19 pandemic in...
Resilience and Pluristyx have entered a strategic collaboration to accelerate and simplify the transition of promising iPSC-derived therapies from...
Event Overview: Join us for an informative webcast with industry experts as they address critical challenges in viral vector manufacturing that...
The proliferation of recombinant protein therapies has driven the need for new capacity in the biotherapeutic manufacturing space. Monoclonal...
How Early-Phase Companies Can Future-Proof Their Cell Therapies The following was extracted from a conversation with Eytan Abraham “Q: How should...
Resilience is proud to announce the official opening of our West Coast (San Diego, CA) Cell Therapy PAD center. This location will serve as our...
For revolutionary gene therapies to reach their full therapeutic potential, high throughput process development workflows are needed to keep pace...